In particular, the AKT-inhibitor molecules PHLDA1 and PHLDA2 are simultaneously upregulated by oncogenic ERK signaling and confer resistance to ERK pathway-targeted therapeutics on cancer cells. The gene discussed is MAPK1; the disease is cancer.